Following are major stock gainers on Nasdaq in Friday’s trading session:
ChemoCentryx, Inc. (NASDAQ:CCXI) was the active stock gainer on Friday and soared 96% to $38. after the biopharmaceutical company received Food and Drug Administration approval for its treatment for a rare autoimmune disease.
ChemoCentryx’s orally administered drug, avacopan, will be sold under the brand name Tavneos. It’s designed to help treat ANCA-associated vasculitis, a condition in which an overreaction in the immune system leads to inflammation and destruction of small blood vessels that can result in fatal organ failure. “Today is a momentous day in the history of ChemoCentryx; the culmination of decades of effort aimed at offering new hope to patients with this and other debilitating and deadly diseases,” CEO Thomas Schall said in a press release.
DatChat, Inc. (NASDAQ:DATS) stock surged 46% to $11.72 as traders circulate bullish commentary from popular traders in the “FinTwit” community. “FinTwit” is an abbreviated term for “Financial Twitter,” which consists of the community of traders and investors who use the Twitter Inc (NYSE: TWTR) platform to share ideas and discuss all things finance related. DatChat seemed to spike higher following bullish comments from one of the more popular members of the FinTwit community, @MrZackMorris.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) moved up 44% to $5.55. Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company’s lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson’s disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington’s disease; VY-FXN01 for Friedreich’s ataxia; and Tau program for the treatment of tauopathies, including Alzheimer’s disease, progressive supranuclear palsy, and frontotemporal dementia.
